



## AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench

### Protocol for Examination of Specimens from Patients with Primary Carcinoma of the Intrahepatic Bile Ducts

**Protocol applies to carcinomas of the intrahepatic bile ducts and combined hepatocellular-cholangiocarcinoma. This protocol does not apply to hepatocellular carcinoma, hepatoblastoma, and carcinomas of the perihilar bile ducts.**

#### Based on:

AJCC/UICC TNM, 7th edition  
CAP Cancer Protocol version 3.1.0.2  
CAP Protocol Web Posting Date: October 2013  
AAPA Macroscopic Examination Template Version 1.0  
AAPA Web Posting Date: March 2017

#### Revision History:

None

#### Summary of Changes:

None

#### Procedures Covered in this Protocol:

- Wedge resection
- Partial hepatectomy
- Total hepatectomy

#### Authors:

Kerri Manhardt, PA(ASCP)\*

Department of Pathology, Kaiser Permanente Foundation Hospital, Hayward, CA

Heidi Cheek, PA(ASCP)

Mayo Clinic, Rochester, MN

Jodi Hilderbrand, PA(ASCP)

Mayo Clinic, Rochester, MN

Courtney Hyland, PA(ASCP)

Mayo Clinic, Rochester, MN

Christine Keeney, PA(ASCP)

Mayo Clinic, Rochester, MN

Monica Kendall, PA(ASCP)

Mayo Clinic, Rochester, MN

Stephanie Miller, PA(ASCP)

Providence Health & Services, Portland, OR

Erika Paulsen, MS, PA(ASCP)

Department of Pathology, Rush University Medical Center, Chicago, IL

Tina Rader, PA(ASCP)

Drexel University College of Medicine, Philadelphia, PA

Mike Sovocool, MHS, PA(ASCP)

Pathology Associates of Syracuse, Syracuse, NY

Dennis Strenk, PA(ASCP)

Ameripath-Milwaukee, Milwaukee, WI

Connie Thorpe, PA(ASCP)

Department of Pathology, Saint Louis University, St. Louis, MO



## AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench

Jon Wagner, PA(ASCP)

Department of Pathology, Sutter Roseville Medical Center, Roseville, CA

\*Denotes primary author. All other contributing authors are listed alphabetically.

### Previous Lead Contributors:

None

### Art Director | Illustrator Liaison:

Jesse McCoy, BFA, PA(ASCP)

Hampton Roads Pathology, Chesapeake Regional Medical Center, Chesapeake, VA

### Illustrator:

Matthew Brownstein



## AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench

### Copyright

© 2017 American Association of Pathologists' Assistants. All rights reserved.

The American Association of Pathologists' Assistants (the "AAPA") hereby authorizes use of The AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench (the "Protocols") solely by pathologists' assistants, pathology residents, and/or pathologists (collectively "Laboratory Personnel") within the laboratories in which they work for the purposes of processing of cancer cases and the education of Laboratory Personnel related to the processing of cancer cases (collectively "Permitted Uses"). The modification or creation of derivative works of the Protocols is prohibited. Any reproduction of the Protocols must be of the complete, unmodified Protocols and solely for the Permitted Uses of the Laboratory Personnel within the laboratories in which they work. Reproduction or distribution of: (a) only a portion of the Protocols; (b) all or a portion of these Protocols outside of the laboratories in which the Laboratory Personnel work; or (c) for commercial use of the Protocols beyond the Permitted Uses, is strictly prohibited.

The purpose of the Protocols is to support Laboratory Personnel engaged in the macroscopic examination of cancer resection specimens. The Protocols are based on specified relevant source documents, drafted by pathologists' assistant experts, and supported by information provided by the College of American Pathologists (CAP) and the American Joint Committee on Cancer (AJCC). These Protocols are intended to serve patients by ensuring that the macroscopic examination of cancer resection specimens is compliant with CAP Cancer Protocols, the AJCC Cancer Staging Manual, and provide optimization of the pre-analytic steps necessary to promote appropriate molecular studies.

The AAPA cautions that the use of the Protocols in practice may require the use of additional considerations that are beyond the scope of the Protocols. The AAPA does not offer medical advice or diagnoses, or engage in the practice of medicine. The information provided in the Protocols is not intended or implied to be a substitute for the Laboratory Personnel's own training, professional medical opinion, diagnosis, or treatment advice. All content, including text, graphics, images and information contained in the Protocols are for the above stated purposes only. Laboratory Personnel are encouraged to confirm any information provided in these Protocols with other sources. The inclusion of a product name, organization, or service in an AAPA publication, including without limitation the Protocols, should not be construed as an endorsement of such product, organization, or service, nor is failure to include the name of a product, organization or service to be construed as disapproval.

THE AAPA IS NOT RESPONSIBLE NOR LIABLE FOR ANY ADVICE, COURSE OF TREATMENT, DIAGNOSIS OR ANY OTHER INFORMATION, SERVICES OR PRODUCTS THAT LABORATORY PERSONNEL PROVIDE WHETHER OR NOT IN RELATION TO USING THE PROTOCOLS. THE AAPA DOES NOT WARRANT OR MAKE ANY REPRESENTATION REGARDING USE, OR THE RESULT OF USE, OF THE CONTENT OF THE PROTOCOLS IN TERMS OF ACCURACY, RELIABILITY, OR OTHERWISE. THE CONTENT OF THE PROTOCOLS MAY INCLUDE TECHNICAL INACCURACIES OR TYPOGRAPHICAL ERRORS, AND THE AAPA MAY MAKE CHANGES OR IMPROVEMENTS AT ANY TIME. YOUR USE OF THESE PROTOCOLS IS AT YOUR OWN RISK. THE CONTENT IS PROVIDED "AS IS" AND WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THE AAPA DISCLAIMS ALL WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NON-INFRINGEMENT.

TO THE FULL EXTENT ALLOWED BY THE LAW, THE AAPA, ITS MEMBERS, AFFILIATES, LICENSORS, SERVICE PROVIDERS, CONTENT PROVIDERS, EMPLOYEES, AGENTS, OFFICERS, AND DIRECTORS (THE "AAPA PARTIES") WILL NOT BE LIABLE FOR ANY INCIDENTAL, DIRECT, INDIRECT, PUNITIVE, ACTUAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR OTHER DAMAGES, INCLUDING LOSS OF REVENUE OR INCOME, PAIN AND SUFFERING, EMOTIONAL DISTRESS, OR SIMILAR DAMAGES IN RELATION TO THE PROTOCOLS, EVEN IF THE AAPA PARTIES HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT WILL THE COLLECTIVE LIABILITY OF THE AAPA PARTIES TO ANYONE IN RELATION TO THE PROTOCOLS (REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT, OR OTHERWISE) EXCEED THE MINIMUM AMOUNT ALLOWED BY LAW. SOME JURISDICTIONS DO NOT ALLOW THE LIMITATION OR EXCLUSION OF LIABILITY OR WARRANTIES FOR CERTAIN TYPES OF DAMAGES. AS A RESULT, THE ABOVE LIMITATIONS OR EXCLUSIONS MAY NOT FULLY APPLY TO YOU.



## AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench

### Immunohistochemistry Considerations:

Greater than 90% of intrahepatic cholangiocarcinomas express keratins 7 and 19, and about 40% also express keratin 20. Most cases are also positive for expression of CEA and CA19-9.

*These tests can be performed on formalin fixed paraffin embedded tissue sections. The macroscopic description should provide the fixative used. Formalin is the preferred fixative. It is recommended that the duration of fixation be provided as well.*

## PROCEDURES AND GENERAL ANATOMIC CONSIDERATIONS:

### ■ Procedures Covered by this Protocol:\*

- Liver wedge resection
- Partial hepatectomy
  - Major hepatectomy (3 segments or more)
  - Minor hepatectomy (less than 3 segments)
- Total hepatectomy


\*This protocol does not apply to hepatocellular carcinoma, hepatoblastoma, and carcinomas of the perihilar bile ducts.

### ■ Specimen Size and Extent of Resection:

- Liver wedge resection – record three dimensions.
- Liver – record three dimensions and weight.
- Gallbladder – record three dimensions.
- Perihilar bile ducts – record length and diameter.
- Record measurements of any other included organs or structures.

### ■ Explanatory Anatomical Notes: (Figure 1)

- The intrahepatic bile ducts extend from the periphery of the liver to the second-order bile ducts.
- The perihilar bile ducts extend from the hepatic duct bifurcation to include the extrahepatic biliary tree proximal to the origin of the cystic duct.
- The distal extrahepatic bile duct extends the junction of the cystic duct/bile duct to the ampulla of Vater.



**Figure 1:** Anatomy of the Intrahepatic and Extrahepatic Biliary System

■ **Specimen Integrity and Adequacy:**\*

- Identify the cut surgical margins and the capsular surface and provide an assessment of specimen integrity.
- Assess the overall appearance of the resected liver (e.g., normal, homogeneous parenchyma with a smooth capsule vs. the nodular and fibrotic appearance of a cirrhotic liver).
- Identify the hepatic vascular pedicle.
  - The vessels and ducts at the porta hepatis constitute the hepatic pedicle and have many variations that are of surgical importance.
- Surgical defect vs tumor perforation of the liver capsule / visceral peritoneum should be clarified.
- Describe evidence of previous surgical procedures (e.g., scar, previous biopsy, etc.).

*\*Statements should include, with as much clarity as can be provided, the anatomic location of the defects or disruptions, and should also incorporate statements which assess the relationship of any defects or disruptions to the tumor. State whether the defect(s) appear to represent a surgical defect or a condition imposed by the tumor (e.g., breach of the liver capsule by tumor). If defects or disruptions involve the tumor and serve to hinder assessment of the final surgical margin this must be stated. Consultation with the surgeon for clarification should be considered as well as differentially inking the margins in areas affected by defects or disruptions as this may assist in creating a post-surgery treatment plan.*


## TUMOR ("T" of TNM)

### ■ Tumor Size:

- Record the tumor size in three dimensions.
- If multiple tumors, count and give dimensions of each or provide a range in size in three dimensions.

### ■ Tumor Site(s): (Figure 2)

- The liver is divided into eight segments, but assignment of the segments on resection specimens is best provided by the surgeon.



**Figure 2: Liver Anatomy - Segments I-VIII with Venous Tracts**

Cantlie's line is a vertical plane that divides the liver into left and right lobes creating the principal plane used for hepatectomy. It extends from the inferior vena cava posteriorly to the middle of the gallbladder fossa anteriorly. It contains the middle hepatic vein which divides the liver into left and right lobes. Segments II, III, IVa and IVb are on the left of the plane, and segments V, VI, VII and VIII are on the right.

## AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench

- State if the tumor is:
  - Subcapsular
  - Parenchymal
  - Vasculocentric
  - Lobar
- Tumor Focality
  - State if the tumor is solitary, and specify the location in segment or lobe of liver.
  - State if there are multiple tumors, and specify the locations in segments or lobes and include the distance from each tumor.
  - Submit sections from each major tumor nodule, and representative sections of smaller nodules if macroscopically different in appearance.

### ■ Tumor Depth of Invasion and Relationship to Attached Organs / Structures:

- Measure tumor to liver capsule.
- Measure tumor to gallbladder/hepatic bed, if present.
- Measure tumor to major vascular structures.
- State if the tumor is:
  - Confined to the liver
  - Involves a major branch of the portal vein
  - Involves 1 or more hepatic vein(s)
  - Involves the visceral peritoneum
  - Directly invades the gallbladder
  - Directly invades other adjacent organs (specify)
  - Describe other macroscopic features (e.g., nodularity, bulging cut surface, hemorrhage, central scar).
- If a tumor has been preoperatively embolized via transarterial chemo-embolization (TACE), macroscopic percentage of tumor necrosis should be assessed.
- Describe tumor configuration.\*

\*Intrahepatic cholangiocarcinoma is characterized by three growth patterns that may coexist:

- Mass-forming type
  - Characteristic firm, white, or gray macroscopic appearance
  - Well-demarcated nodule growing in a radial pattern and invading liver parenchyma
- Periductal infiltrating type
  - Spreads in a diffuse longitudinal growth pattern along the bile duct
- Mixed mass-forming/periductal infiltrating type

## AAPA Macroscopic Examination Guidelines: Utilization of the CAP Cancer Protocols at the Surgical Gross Bench

<b>Primary Tumor (T)</b>	
pTX	<b>Primary tumor cannot be assessed</b>
pT0	<b>No evidence of primary tumor</b>
pTis	<b>Carcinoma in situ (intraductal tumor)</b>
pT1	<b>Solitary tumor without vascular invasion*</b>
pT2a	<b>Solitary tumor with vascular invasion</b>
pT2b	<b>Multiple tumors**, with or without vascular invasion</b>
pT3	<b>Tumor perforating the visceral peritoneum or involving the local extrahepatic structures by direct invasion</b>
pT4	<b>Tumor with periductal invasion***</b>

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, [www.springer.com](http://www.springer.com).

\*Note that the presence of vascular invasion is the difference between pT1 and pT2 tumors. Vascular invasion can refer to macroscopic tumor invasion of large vessels or microscopic involvement of small vessels. Ensure sufficient tumor tissue is submitted for identification of vascular invasion.

\*\*All multiple tumor nodules are considered equal for the purpose of staging. There is no difference between satellite nodules, multifocal primary cholangiocarcinomas and intrahepatic metastases.

\*\*\*Tumors with the periductal infiltrating pattern invade the length of the duct longitudinally instead of forming a mass that infiltrates into the surrounding parenchyma. This type of tumor growth pattern (including the mixed variant of the two) may be associated with a poor prognosis and is considered stage T4.

### *TNM Descriptors*

*cTNM:* The “c” prefix is used when clinical staging is performed by the referring physician or when pathological assessment is not possible.

*pT(m)NM:* The “m” suffix is added within parentheses after the pT indicator and is used when there are multiple primary tumors within a single site.

*ypTNM:* The “y” prefix is used when neoadjuvant therapy has been performed.

*rTNM:* The “r” prefix is used when tumor recurrence is staged after a disease-free interval.

*aTNM:* The “a” prefix indicates when the stage is determined at autopsy.

## ■ ADDITIONAL SECTIONS

Additional sections of unininvolved liver parenchyma should be submitted for sufficient evaluation for hepatobiliary parasitosis, chronic viral hepatitis and primary sclerosing cholangitis, all of which are predisposing factors to cholangiocarcinoma.

## ■ Margins:

Evaluation of margins for total or partial hepatectomy specimens depends on the method and extent of resection. Consultation with the surgeon is recommended to determine the critical foci within the margins that require microscopic evaluation.

### ■ Hepatectomy

- Submit representative sections of all margins at the closest approach of the tumor.
- Submit vascular margins (if identified).
- Gallbladder hepatic bed margin.
- Bile duct margin
  - State if the bile duct margin is involved or unininvolved by tumor.

### ■ Partial hepatectomy resection margin

- Apply ink to the surgical resection margin.
- State if the parenchymal margin is unininvolved or involved by tumor.
- If margins are macroscopically free of tumor, judicious sampling of the margin in the region closest to the nearest identified tumor nodule is indicated.
- Take sections of the bile ducts at the margin to evaluate the lining epithelium for in situ carcinoma or dysplasia.
- Record the distance of tumor from the closest margin.
- For multiple tumors, record the distance of the nearest tumor to the margin.
- Submit vascular margins (if identified).
- Gallbladder hepatic bed margin, if present.
- Other margins would include those of attached structures / organs.
  - State if margins are unininvolved or involved by tumor.

## ■ Explanatory Notes:

*Surgery for partial hepatectomy may or may not follow anatomic boundaries. Consequently, before sectioning, it is important to understand the procedure that was performed; review the imaging studies and reports, and consult with the surgeon if necessary. Often, the perihilar bile duct margins will be evaluated by frozen section analysis. If no frozen section is performed, ensure the documentation of margins prior to dissection.*

## LYMPH NODES ("N" of TNM)

- **Lymph Nodes:** (if applicable)

<b>pNX</b>	<b>Cannot be assessed</b>
<b>pN0</b>	<b>No regional lymph node metastasis</b>
<b>pN1</b>	<b>Regional lymph node metastasis</b>

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, [www.springer.com](http://www.springer.com).

The lymph node drainage patterns from the intrahepatic bile ducts demonstrate laterality. Lymph node involvement patterns for intrahepatic bile duct tumors varies with location in the liver.

### Regional lymph nodes

- Right lobe biliary tumors (segments 5-8):
  - Hilar lymph nodes (common bile duct, hepatic artery, portal vein and cystic duct)
  - Periportal lymph nodes
  - Peripancreatic lymph nodes
- Left lobe tumors (segments 2-3):
  - Hilar
  - Gastrohepatic lymph nodes

Note: Celiac, periaortic or caval lymph nodes are considered to be distant metastasis. Inferior phrenic nodes are considered regional nodes.

### Histologic examination of a regional lymphadenectomy specimen usually involves examination of 3 or more lymph nodes:

- State the number of lymph nodes identified.
- Specify the location, if known.
- Measure the lymph nodes in three dimensions.
- Describe the cut surface of the lymph nodes.
- Submit all lymph nodes for microscopic examination.
  - Submit small lymph nodes in toto.
  - Section and entirely submit larger macroscopically negative lymph nodes.
  - Representative sections from macroscopically positive nodes are adequate.
- If possible, submit lymph sections so that the long axis of the lymph node can be demonstrated.
- Take steps to ensure that an accurate lymph node count can be rendered.

- **Explanatory Notes:**

Direct invasion of the portal lymph nodes is considered a T3 disease and not as metastases.

## METASTASIS ("M" of TNM)

■ **Metastasis:**

<b>pM0</b>	<b>No distant metastasis</b>
<b>pM1</b>	<b>Distant metastasis</b>

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, [www.springer.com](http://www.springer.com).

- Intrahepatic cholangiocarcinomas commonly metastasize to other sites within the liver (referenced in the pT2b classification - multiple tumors) and to the peritoneum, lungs and pleura.
- Nodal involvement of the celiac, periaortic, or caval lymph nodes are considered to be distant metastasis instead of regional nodal involvement.
- Extraregional nodal involvement and other distant metastatic sites are classified as M1 disease.

■ **Explanatory Notes:**

Direct invasion of adjacent organs, including colon, stomach, duodenum, common bile duct, portal lymph nodes, abdominal wall, and diaphragm is considered T3 disease and is not considered distant metastases.

**REFERENCE REVIEW:**

1. Berdah SV, Delpero JR, Garcia S, Hardwigsen J, Le Treut YP. A western surgical experience of peripheral cholangiocarcinoma. *Br J Surg.* 1996;83(11):157-21.
2. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. *Br J Surg.* 2002;89(12):1525-31.
3. Yamamoto M, Takasaki K, Yoshikawa T. Extended resection for intrahepatic cholangiocarcinoma in Japan. *J Hepatobiliary Pancreat Surg.* 1999;6(2):117-21.
4. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. *J Hepatobiliary Pancreat Surg.* 2003;10(4):288-91.
5. Edge S, Byrd DR, Compton CC, Fritz AG, et al. (Eds.) *AJCC Cancer Staging Manual*, 7th ed. New York; NY: Springer; 2010.
6. Humphrey PA, Dehner LP, & Pfeifer JD. *The Washington manual of surgical pathology*, 2nd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2012.
7. Tang LH, Berlin J, Branton P, et al. Protocol for the Examination of Specimens from Patients with Carcinoma of the Intrahepatic Bile Ducts. *CAP Cancer Protocol* 3.1.0.2. 2013.